<DOC>
	<DOCNO>NCT00548821</DOCNO>
	<brief_summary>The primary aim research protocol compare difference progression free survival weekly versus 5-day 3 weekly cisplatin base chemotherapy regimen woman locally advanced cervical cancer . The secondary aim compare quality life assessment patient carers well toxicity profile acute late .</brief_summary>
	<brief_title>Randomized Trial Between Weekly 5 Day 3 Weekly Cisplatin Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>stage IB2IVA , histological proven cervical carcinoma previous diagnosis carcinoma prior history chemotherapy radiotherapy ECOG le equal 2 Above 21 year old medically fit radical concurrent Cisplatin base chemotherapy radiotherapy Hemoglobin &gt; 10g/dL Adequate hematological , renal hepatic function accord follow laboratory value : Absolute neutrophil count ≥ 1.5 ×109/l Platelets ≥ 100 ×109/l Serum creatinine ≤ 1.5 time upper limit laboratory normal Total serum bilirubin ≤ 1.5 time upper limit laboratory normal ASAT ( AST ) ALAT ( ALT ) ≤ 2.5 time upper limit laboratory normal Alkaline phosphatase ≤ 2.5 time upper limit laboratory normal Age 21 Presence know HIV infection , chronic hepatitis B hepatitis C infection Psychological , familial , sociological , geographical condition would preclude study participation Prior ( within last 3 year ) simultaneous malignancy ( cutaneous basal cell carcinoma noninvasive tumor ) Patients follow histology exclude : small cell , carcinoid , glassy cell , clear cell adenoid cystic . Life expectancy &lt; 6 month Patients insulin dependent diabetes Prior tumordirected surgery Previous systemic chemotherapy pelvic radiation therapy As radiation cytotoxic agent contraindicated pregnancy , pregnant woman ineligible childbearing potential use contraception</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>